share_log

Gyre Therapeutics | 10-Q: Quarterly report

Gyre Therapeutics | 10-Q: Quarterly report

Gyre Therapeutics | 10-Q：季度报表
美股SEC公告 ·  2024/08/13 15:07

Moomoo AI 已提取核心信息

Gyre Therapeutics reported Q2 2024 revenue of $25.2 million, down 14% YoY from $29.3 million, primarily due to normalized anti-fibrosis drug sales following the 2023 COVID-related surge. Net income increased 20% to $4.5 million, with net income attributable to common stockholders up 90% to $3.5 million. The company maintained a strong gross margin of 97% despite revenue decline.Research and development expenses decreased 6% to $3.4 million as the company advanced its key programs, including F351 for liver fibrosis. General and administrative expenses rose to $3.4 million due to public company costs. The company ended the quarter with $16.1 million in cash and cash equivalents, $9.0 million in short-term deposits, and $28.8 million in long-term certificates of deposit.Looking ahead, Gyre Therapeutics is expanding its product portfolio with the acquisition of nintedanib rights for IPF treatment and recent NMPA approval of avatrombopag for thrombocytopenia. The company expects to submit an IND application for F351 in late 2024 and initiate a Phase 2a trial for NASH-associated liver fibrosis in 2025, supported by its strong financial position and commercial infrastructure.
Gyre Therapeutics reported Q2 2024 revenue of $25.2 million, down 14% YoY from $29.3 million, primarily due to normalized anti-fibrosis drug sales following the 2023 COVID-related surge. Net income increased 20% to $4.5 million, with net income attributable to common stockholders up 90% to $3.5 million. The company maintained a strong gross margin of 97% despite revenue decline.Research and development expenses decreased 6% to $3.4 million as the company advanced its key programs, including F351 for liver fibrosis. General and administrative expenses rose to $3.4 million due to public company costs. The company ended the quarter with $16.1 million in cash and cash equivalents, $9.0 million in short-term deposits, and $28.8 million in long-term certificates of deposit.Looking ahead, Gyre Therapeutics is expanding its product portfolio with the acquisition of nintedanib rights for IPF treatment and recent NMPA approval of avatrombopag for thrombocytopenia. The company expects to submit an IND application for F351 in late 2024 and initiate a Phase 2a trial for NASH-associated liver fibrosis in 2025, supported by its strong financial position and commercial infrastructure.
Gyre Therapeutics报告2024年第二季度营业收入为2520万，较去年同期的2930万下降14%，主要是由于2023年因COVID相关激增后抗纤维化药物销售恢复正常。净利润增长20%，达到450万，归属于普通股股东的净利润增至350万，增长90%。尽管收入下降，公司仍保持了97%的高毛利率。研发支出下降6%，至340万，因为公司在推进其关键项目，包括用于肝纤维化的F351。由于上市公司成本，一般和管理费用上升至340万。公司季度末的现金及现金等价物为1610万，短期存入资金为900万，以及长期存款为2880万。展望未来，Gyre Therapeutics正在通过收购nintedanib用于IPF治疗的权利和最近NMPA批准的avatrombopag用于血小板减少症，扩展其产品组合。公司预计将在2024年末提交F351的IND申请，并于2025年启动针对NASH相关肝纤维化的2a期临床试验，得到其强大财务状况和商业制造行业的支持。
Gyre Therapeutics报告2024年第二季度营业收入为2520万，较去年同期的2930万下降14%，主要是由于2023年因COVID相关激增后抗纤维化药物销售恢复正常。净利润增长20%，达到450万，归属于普通股股东的净利润增至350万，增长90%。尽管收入下降，公司仍保持了97%的高毛利率。研发支出下降6%，至340万，因为公司在推进其关键项目，包括用于肝纤维化的F351。由于上市公司成本，一般和管理费用上升至340万。公司季度末的现金及现金等价物为1610万，短期存入资金为900万，以及长期存款为2880万。展望未来，Gyre Therapeutics正在通过收购nintedanib用于IPF治疗的权利和最近NMPA批准的avatrombopag用于血小板减少症，扩展其产品组合。公司预计将在2024年末提交F351的IND申请，并于2025年启动针对NASH相关肝纤维化的2a期临床试验，得到其强大财务状况和商业制造行业的支持。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Forte Biosciences
    FBRX
    -- 8.510
    Plus Therapeutics
    PSTV
    -- 1.4300
    IO Biotech
    IOBT
    -- 1.170
    Celularity
    CELU
    -- 2.1500
    Tiziana Life Sciences
    TLSA
    -- 1.2300
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    FOMC维持利率但不确定性高企：美股后市走向如何？
    🎙️讨论 1. 美联储强调政策路径存在“高度不确定性”，你更关注利率预期变化还是经济数据对市场的短期影响？ 2. 若核心通胀维持高位，哪类板块更具交易机会——防御型股票还是科技成长股？ 展开
    联邦公开市场委员会新闻发布会，2025年3月19日